Asset Details
Do you wish to reserve the book?
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models
Do you wish to request the book?
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models
2018
Overview
Alpha-synuclein is a component of Lewy bodies, the pathological hallmark of Parkinson’s disease (PD), and is also mutated in familial PD. Here, by extensively analyzing PD patient brains and neurons, and fly models, we show that alpha-synuclein accumulation results in upregulation of Miro protein levels. Miro is a motor/adaptor on the outer mitochondrial membrane that mediates mitochondrial motility, and is removed from damaged mitochondria to facilitate mitochondrial clearance via mitophagy. PD patient neurons abnormally accumulate Miro on the mitochondrial surface leading to delayed mitophagy. Partial reduction of Miro rescues mitophagy phenotypes and neurodegeneration in human neurons and flies. Upregulation of Miro by alpha-synuclein requires an interaction via the N-terminus of alpha-synuclein. Our results highlight the importance of mitochondria-associated alpha-synuclein in human disease, and present Miro as a novel therapeutic target.
Publisher
Springer Nature B.V
